6CM
IMRX icon

683 Capital Management’s Immuneering IMRX Stock Holding History

683 Capital Management’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$794K Hold
150,697
– – 0.04% 149
2025
Q4 		$992K Buy
+150,697
New +$968K 0.04% 142

Other funds holding IMRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
OCM
Occam Crest Management Darien, Connecticut $165M AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

683 Capital Management's IMRX Position: Q1 2026 in Review

683 Capital Management held its Immuneering (IMRX) position steady in Q1 2026 at 150,697 shares worth $794K. The position accounts for 0.04% of the portfolio, ranked #149.

683 Capital Management first reported a position in IMRX in Q4 2025 and has held it in 2 quarters since. The position peaked at $992K in Q4 2025. 95 funds tracked by Wall St. Rank hold IMRX as of Q1 2026.

  • 683 Capital Management held 150,697 shares of Immuneering worth $794K as of Q1 2026.
  • 683 Capital Management left its Immuneering share count unchanged in Q1 2026.
  • Immuneering made up 0.04% of 683 Capital Management's portfolio in Q1 2026, its #149 holding.
  • 683 Capital Management first reported a position in Immuneering in Q4 2025 and has held it in 2 quarters since.
  • 683 Capital Management's Immuneering position peaked at $992K in Q4 2025.
  • 95 funds tracked by Wall St. Rank held Immuneering as of Q1 2026.

Based on 683 Capital Management's 13F filing for Q1 2026, filed 15 May 2026.